CoNotes

"Adimab is changing the discovery, maturation and production of fully human therapeutic antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab selects high affinity human antibodies with improved formulation and manufacturing characteristics. Our proprietary library design and presentation technologies enable the discovery of full-length human antibodies with broad epitope coverage and high affinity – faster than any known technology platform.

Conventional antibody discovery is a lengthy process that involves a myriad of different technologies that need to be assembled before a commercial antibody can be produced. The integration of: (i) library design, (ii) display methodology, (iii) reformatting between different hosts and expression constructs, and (iv) GMP cell line development is resource intensive, time consuming, and typically results in extensive royalty obligations to multiple third parties."

Source: Admilab